NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $17.62 +1.85 (+11.73%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$15.83▼$18.1450-Day Range$15.77▼$36.5852-Week Range$11.66▼$42.60Volume350,083 shsAverage Volume197,864 shsMarket Capitalization$313.57 millionP/E RatioN/ADividend YieldN/APrice Target$43.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cartesian Therapeutics alerts: Email Address Cartesian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside148.8% Upside$43.83 Price TargetShort InterestHealthy11.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.06Based on 20 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $2.28 to ($3.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.05 out of 5 starsMedical Sector308th out of 896 stocksPharmaceutical Preparations Industry143rd out of 424 stocks 4.4 Analyst's Opinion Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCartesian Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cartesian Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.69% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Cartesian Therapeutics has recently decreased by 10.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNAC. Previous Next 1.6 News and Social Media Coverage News SentimentCartesian Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Cartesian Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for RNAC on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders61.10% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from $2.28 to ($3.23) per share.Read more about Cartesian Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Cartesian Therapeutics Stock (NASDAQ:RNAC)Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Read More RNAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNAC Stock News HeadlinesJuly 4 at 4:50 AM | americanbankingnews.comHC Wainwright Lowers Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $49.00July 4 at 4:00 AM | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) PT Raised to $43.00 at Canaccord Genuity GroupJuly 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 3 at 3:12 AM | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Downgraded by Oppenheimer to "Market Perform"July 2 at 4:05 PM | globenewswire.comCartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikJuly 2 at 10:55 AM | investors.comCartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T DrugsJuly 2 at 6:40 AM | reuters.comCartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage studyJuly 2 at 6:31 AM | globenewswire.comCartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus ErythematosusJuly 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 2 at 6:31 AM | globenewswire.comCartesian Therapeutics Announces $130 Million Private Placement Equity FinancingJuly 2 at 6:30 AM | globenewswire.comCartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia GravisJuly 2 at 3:42 AM | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Receives "Buy" Rating from Needham & Company LLCJune 29, 2024 | americanbankingnews.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Buy" by BrokeragesJune 26, 2024 | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Rating Reiterated by OppenheimerJune 6, 2024 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantMay 24, 2024 | msn.comMizuho Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy RecommendationMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic PositioningMay 24, 2024 | msn.comMizuho starts Cartesian at buy, cites lead drug assetMay 22, 2024 | msn.comCartesian stock climbs 8% on FDA regenerative therapy designationMay 22, 2024 | markets.businessinsider.comCartesian: FDA Grants Regenerative Medicine Advanced Therapy Designation For Descartes-08May 22, 2024 | globenewswire.comCartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia GravisMay 17, 2024 | edition.cnn.comCartesian Therapeutics, Inc.May 13, 2024 | globenewswire.comCartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 13, 2024 | benzinga.comWhat Makes Cartesian Therapeutics, Inc. a New Buy StockMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic ExpansionMay 10, 2024 | finance.yahoo.comCartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cartesian Therapeutics with Promising Descartes-08 Therapy Outlook and Strong FinancialsSee More Headlines Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/05/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CUSIPN/A CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees37Year FoundedN/APrice Target and Rating Average Stock Price Target$43.83 High Stock Price Target$50.00 Low Stock Price Target$39.00 Potential Upside/Downside+148.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-219,710,000.00 Net Margins-983.93% Pretax Margin-1,057.17% Return on EquityN/A Return on Assets-18.77% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio3.03 Sales & Book Value Annual Sales$26 million Price / Sales12.06 Cash FlowN/A Price / Cash FlowN/A Book Value($82.38) per share Price / Book-0.21Miscellaneous Outstanding Shares17,800,000Free Float6,923,000Market Cap$313.64 million OptionableOptionable Beta0.66 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Carsten Brunn Ph.D. (Age 52)President, CEO & Director Comp: $4.67MMr. Blaine T. Davis (Age 49)Chief Financial Officer Comp: $2.49MDr. Metin Kurtoglu M.D. (Age 45)Ph.D., Chief Technology Officer Comp: $398.28kKey CompetitorsStructure TherapeuticsNASDAQ:GPCRCatalyst PharmaceuticalsNASDAQ:CPRXArvinasNASDAQ:ARVNMaravai LifeSciencesNASDAQ:MRVISyndax PharmaceuticalsNASDAQ:SNDXView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 9,136,635 shares on 5/17/2024Ownership: 171.098%American International Group Inc.Bought 56,202 shares on 5/14/2024Ownership: 1.052%Vanguard Group Inc.Bought 6,315,113 shares on 5/10/2024Ownership: 118.172%SG Americas Securities LLCBought 47,134 shares on 5/7/2024Ownership: 0.883%Delphi Financial Group Inc.Bought 660,852 shares on 5/3/2024Ownership: 12.261%View All Insider TransactionsView All Institutional Transactions RNAC Stock Analysis - Frequently Asked Questions Should I buy or sell Cartesian Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cartesian Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RNAC shares. View RNAC analyst ratings or view top-rated stocks. What is Cartesian Therapeutics' stock price target for 2024? 7 equities research analysts have issued 12-month price objectives for Cartesian Therapeutics' shares. Their RNAC share price targets range from $39.00 to $50.00. On average, they anticipate the company's stock price to reach $43.83 in the next twelve months. This suggests a possible upside of 148.8% from the stock's current price. View analysts price targets for RNAC or view top-rated stocks among Wall Street analysts. How have RNAC shares performed in 2024? Cartesian Therapeutics' stock was trading at $20.6820 at the beginning of 2024. Since then, RNAC stock has decreased by 14.8% and is now trading at $17.62. View the best growth stocks for 2024 here. When is Cartesian Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024. View our RNAC earnings forecast. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its earnings results on Wednesday, May, 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $1.16. The company had revenue of $5.84 million for the quarter. When did Cartesian Therapeutics' stock split? Shares of Cartesian Therapeutics reverse split before market open on Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNAC) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.